zonisamide has been researched along with Essential Tremor in 9 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Essential Tremor: A relatively common disorder characterized by a fairly specific pattern of tremors which are most prominent in the upper extremities and neck, inducing titubations of the head. The tremor is usually mild, but when severe may be disabling. An autosomal dominant pattern of inheritance may occur in some families (i.e., familial tremor). (Mov Disord 1988;13(1):5-10)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide at a dose of 25 mg per day did not improve tremor in tremor-dominant PD patients, however, a positive trend was seen as compared to Placebo in the UPDRS tremor score." | 9.51 | Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial. ( Bhat, P; Elavarasi, A; Goyal, V; Pandit, AK; Pillai, KS; Prasad, K; Radhakrishnan, DM; Rajan, R; Singh, MB; Srivastava, AK; Srivastava, MP; Vishnu, VY, 2022) |
| "We performed a pilot, crossover trial of zonisamide (ZNS) on essential tremor patients." | 9.11 | Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. ( Kondo, T; Miwa, H; Morita, S, 2005) |
| "To assess the effect on functional abilities and the safety profile of zonisamide in adults with essential tremor (ET)." | 8.95 | Zonisamide for essential tremor. ( Bruno, E; Colosimo, C; Filippini, G; Nicoletti, A; Quattrocchi, G; Zappia, M, 2017) |
| "In this evaluator-blinded open-treatment trial, subjects with moderate/severe upper limb essential tremor were titrated to 300 mg/day zonisamide, or adjusted to a lesser dose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12-week extension phase." | 7.75 | Zonisamide for essential tremor: an evaluator-blinded study. ( Handforth, A; Kang, GA; Martin, FC; Vanek, Z, 2009) |
| " ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14." | 6.73 | A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. ( Hauser, RA; Sanchez-Ramos, J; Staffetti, JF; Sullivan, KL; Ward, CL; Zesiewicz, TA, 2007) |
| "Zonisamide at a dose of 25 mg per day did not improve tremor in tremor-dominant PD patients, however, a positive trend was seen as compared to Placebo in the UPDRS tremor score." | 5.51 | Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial. ( Bhat, P; Elavarasi, A; Goyal, V; Pandit, AK; Pillai, KS; Prasad, K; Radhakrishnan, DM; Rajan, R; Singh, MB; Srivastava, AK; Srivastava, MP; Vishnu, VY, 2022) |
| "We performed a pilot, crossover trial of zonisamide (ZNS) on essential tremor patients." | 5.11 | Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. ( Kondo, T; Miwa, H; Morita, S, 2005) |
| "To assess the effect on functional abilities and the safety profile of zonisamide in adults with essential tremor (ET)." | 4.95 | Zonisamide for essential tremor. ( Bruno, E; Colosimo, C; Filippini, G; Nicoletti, A; Quattrocchi, G; Zappia, M, 2017) |
| "In this evaluator-blinded open-treatment trial, subjects with moderate/severe upper limb essential tremor were titrated to 300 mg/day zonisamide, or adjusted to a lesser dose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12-week extension phase." | 3.75 | Zonisamide for essential tremor: an evaluator-blinded study. ( Handforth, A; Kang, GA; Martin, FC; Vanek, Z, 2009) |
| " ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14." | 2.73 | A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. ( Hauser, RA; Sanchez-Ramos, J; Staffetti, JF; Sullivan, KL; Ward, CL; Zesiewicz, TA, 2007) |
| "Essential tremor is a common disorder that lacks molecular targets for therapeutic development." | 1.36 | T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. ( Covey, DF; Handforth, A; Homanics, GE; Krishnan, K; Lee, JY; Martin, FC; Quesada, A; Sakimura, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Pillai, KS | 1 |
| Bhat, P | 1 |
| Srivastava, AK | 1 |
| Rajan, R | 1 |
| Radhakrishnan, DM | 1 |
| Elavarasi, A | 1 |
| Srivastava, MP | 1 |
| Singh, MB | 1 |
| Vishnu, VY | 1 |
| Prasad, K | 1 |
| Pandit, AK | 1 |
| Goyal, V | 1 |
| Bruno, E | 1 |
| Nicoletti, A | 1 |
| Filippini, G | 1 |
| Quattrocchi, G | 1 |
| Colosimo, C | 1 |
| Zappia, M | 1 |
| Song, IU | 1 |
| Kim, JS | 1 |
| Lee, SB | 1 |
| Ryu, SY | 1 |
| An, JY | 1 |
| Kim, HT | 1 |
| Kim, YI | 1 |
| Lee, KS | 1 |
| Handforth, A | 2 |
| Martin, FC | 2 |
| Kang, GA | 1 |
| Vanek, Z | 1 |
| Homanics, GE | 1 |
| Covey, DF | 1 |
| Krishnan, K | 1 |
| Lee, JY | 1 |
| Sakimura, K | 1 |
| Quesada, A | 1 |
| Morita, S | 1 |
| Miwa, H | 1 |
| Kondo, T | 1 |
| Sullivan, KL | 2 |
| Ward, CL | 2 |
| Zesiewicz, TA | 2 |
| Hauser, RA | 1 |
| Sanchez-Ramos, J | 1 |
| Staffetti, JF | 1 |
| Bermejo, PE | 1 |
1 review available for zonisamide and Essential Tremor
| Article | Year |
|---|---|
Zonisamide for essential tremor.
Topics: Anticonvulsants; Essential Tremor; Humans; Isoxazoles; Randomized Controlled Trials as Topic; Zonisa | 2017 |
5 trials available for zonisamide and Essential Tremor
| Article | Year |
|---|---|
Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial.
Topics: Double-Blind Method; Essential Tremor; Humans; Parkinson Disease; Treatment Outcome; Tremor; Zonisam | 2022 |
Effects of zonisamide on isolated head tremor.
Topics: Adrenergic beta-Antagonists; Aged; Anticonvulsants; Consciousness Disorders; Dose-Response Relations | 2008 |
Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anticonvulsants; Cross-Over Studies; Essentia | 2005 |
A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Electrophysiology; Equipment | 2007 |
Zonisamide in patients with essential tremor and Parkinson's disease.
Topics: Anticonvulsants; Essential Tremor; Humans; Isoxazoles; Parkinson Disease; Zonisamide | 2007 |
3 other studies available for zonisamide and Essential Tremor
| Article | Year |
|---|---|
Zonisamide for essential tremor: an evaluator-blinded study.
Topics: Aged; Anticonvulsants; Drug Administration Schedule; Essential Tremor; Female; Humans; Isoxazoles; M | 2009 |
T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.
Topics: Analysis of Variance; Animals; Benzimidazoles; Calcium Channel Blockers; Calcium Channels, T-Type; C | 2010 |
Zonisamide-induced mania in an essential tremor patient.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Essential Tremor; Female; Humans; Isoxazoles; Zonisamide | 2006 |